A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Start Date
6/22/2026
Completion Date
7/23/2035
Summary
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
MK-1045
Rituximab
Rituximab biosimilar
Bendamustine
Cyclophosphamide
Vincristine
Prednisone
Prednisolone
Doxorubicin Hydrochloride
Conditions
Locations
SCRI Oncology Partners ( Site 7000)
Nashville, Tennessee 37203
United States
Hadassah Medical Center ( Site 0701)
Jerusalem, 9112001
Israel
Sheba Medical Center ( Site 0702)
Ramat Gan, 5265601
Israel
Sourasky Medical Center ( Site 0704)
Tel Aviv, 6423906
Israel
Institut Català d'Oncologia (ICO) - Badalona ( Site 0904)
Badalona, Barcelona 08916
Spain
Hospital Virgen de la Victoria ( Site 0905)
Málaga, Malaga 29010
Spain
Hospital Universitari Vall de Hebron ( Site 0903)
Barcelona, 08035
Spain
Hospital Universitario Gregorio Maranon ( Site 0902)
Madrid, 28007
Spain
Hospital Universitario de Salamanca ( Site 0906)
Salamanca, 37007
Spain
Chang Gung Medical Foundation-Linkou Branch ( Site 1002)
Taoyuan, 333
Taiwan
Hacettepe Universite Hastaneleri ( Site 1110)
Ankara, 06230
Turkey (Türkiye)
Sisli Florence Nightingale Hastanesi ( Site 1112)
Istanbul, 34381
Turkey (Türkiye)
Ondokuz Mayıs Universitesi ( Site 1113)
Samsun, 55270
Turkey (Türkiye)